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Abstract 
We present a long followed up case of acute central serous chorioretinopathy (CSC) 
complicated by a severe visual loss due to massive pigment epithelium detachment of the 
macula after a full-dose photodynamic therapy (PDT). Rapid anatomical and functional 
improvement was observed after a single intravitreal injection of bevacizumab. To our 
knowledge, we report the first case of PDT-treated CSC complicated by severe visual loss. 
We can only speculate that the serous detachment of the posterior pole might have been 
caused by PDT-induced VEGF overexpression, explaining such an impressive response to 
Avastin treatment. 
 
Introduction 
During the period 2000–2005, photodynamic therapy (PDT) with verteporfin was 
considered a therapy of choice for certain conditions with choroidal neovascularisation 
(CNV). Conventional PDT has been also described as an effective and safe therapeutic 
option for central serous chorioretinopathy (CSC) [1]. 
Case Report 
A 56-year-old woman presented to our emergency care unit for OD painless vision reduction and 
metamorphopsia lasting for 2 days. Her best corrected visual acuity (BCVA) was 0.7 OD and 1.0 OS.  
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General health and ocular history were unremarkable. Fundus examination and OCT3 imaging 
revealed a foveal neuroretinal detachment and fluorescein angiography (FA) showed two juxtafoveal 
points of leakage (fig. 1). The patient was put under observation. Two weeks later she presented with 
further vision deterioration and she stated for special vision demands. Her OD BCVA dropped to 0.4 
and she agreed to be treated by PDT. Conventional dose of verteporfin infusion and laser energy 
parameters used in our patient were identical to those used in the TAP study [2] and the laser spot 
size of 3,000 μm was centered on the angiographic leakage in the FA. Only twelve hours later the 
patient noticed severe vision loss in the treated eye. BCVA was reduced to 0.025 and fundus 
examination revealed a massive macular detachment. A large serous pigment epithelium detachment 
was apparent on OCT. Fluorescein and indocyanine green angiography showed a dark choroidal 
nonperfusion area with a late hyperfluorescence in FA (fig. 2) giving an impression of occult CNV. 
Fifteen days after PDT the visual acuity remained unchanged. After signing an informed consent, the 
patient underwent an intravitreal injection of bevacizumab (Avastin) 1.25 mg in 0.05 ml. In the 
following fifteen days, submacular fluid was progressively absorbed together with BCVA 
improvement that was 0.4 at the fifteenth day after injection, 0.8 at the first month and 0.9 at months 
three and six (fig. 3). At the last follow-up visit, almost 5 years since CSC involvement, BCVA remains 
stable and the integrity of the involved macular area is apparent on OCT. 
Discussion 
Pathophysiology of CSC remains partly unclear and treatment modalities outcomes 
have not concluded in a standard treatment protocol. Thermal laser photocoagulation 
treatment at the leaking spot has been used for decades if not too close to the foveola 
[1]. The rationale of using PDT for submacular fluid resolution is based on the 
observation that the foci of subretinal fluorescein leakage are usually accompanied by 
choroidal vascular hyperpermeability, this being a therapeutic target of PDT [1]. 
To our knowledge, we report the first case of PDT-treated CSC complicated by severe 
visual loss. According to the TAP study, there are few cases of PDT complicated by 
severe visual loss due mostly to massive subretinal hemorrhage and, rarely, to massive 
detachment of the posterior pole. However, these complications were reported for CNV 
cases only [3]. 
Although PDT has been reported as a safe treatment in CSC, in rare cases it can be 
complicated with extensive choroidal vascular damage and VEGF overexpression [4]. 
We believe that the immediate anatomical and visual improvement after we treated our 
patient with antiVEGF agent was due to the reduction of PDT-induced VEGF 
overexpression. 
The last years, half-dose verteporfin was suggested as a precaution against 
permanent retinal pigment epithelium or choriocapillaris damage [5]. Recently, 
favourable results were also reported in patients with acute type CSC treated with half-
dose verteporfin [5], the safe lowest effective dose being reported as 30% of the full 
dose [6]. Unfortunately it was not a usual clinical practice at the time we treated our 
patient. Hopefully, the reduction of the PDT dose will also protect against 
posttreatment severe visual loss. 
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Fig. 1. Fluorescein angiography at the baseline visit revealing two juxtafoveal points of leakage. Best 
corrected visual acuity is 0.7. 
 
 
 
Fig. 2. Fluorescein and indocyanine green angiography at the day following the PDT session, showing 
a dark choroidal nonperfusion area with a late hyperfluorescence in FA due to serous pigment 
epithelium detachment. Best corrected visual acuity is 0.025. 
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Fig. 3. OCT image 6 months after the Avastin injection, depicting a complete absorption of the fluid. 
Best corrected visual acuity is 0.9. 
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